Alzheimer's Disease Research Center

阿尔茨海默病研究中心

• 批准号: 10461180
• 负责人: SUZANNE CRAFT
• 金额: $ 305.32万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10461180
• 关键词: Address; Adult; African American; African American population; Age; Aging; Alzheimer' s Disease; Alzheimer' s disease risk; American; Amyloid; Area; Biological Markers; Blood Vessels; Capsicum; Clinical; Clinical Sciences; Clinical Trials; Cognition; Collaborations; Communities; Complex; Data; Dementia; Diabetes Mellitus; Disease; Doctor of Philosophy; Early Intervention; Ecosystem; Education; Elderly; Enrollment; Ensure; Epidemic; Faculty; Faculty Recruitment; Family; Family health status; Foundations; Functional disorder; Funding; General Population; Goals; Grant; Health Professional; Heterogeneity; High Prevalence; Human; Hypertension; Impaired cognition; Infrastructure; Institutes; Intervention Trial; Leadership; Magnetic Resonance Imaging; Medical; Metabolic; Metabolic Diseases; Methods; Mission; Modeling; Neurosciences; Participant; Patient Education; Patients; Phase Transition; Play; Positron-Emission Tomography; Prediabetes syndrome; Predictive Factor; Prevalence; Prevention; Prevention strategy; Publications; Reduce health disparities; Research; Research Activity; Research Infrastructure; Research Personnel; Resources; Risk; Risk Factors; Role; Sampling; Statistical Data Interpretation; Strategic Planning; Symptoms; Training; Translational Research; Underrepresented Populations; Vascular Diseases; Work; behavioral neurology; clinical center; clinical implementation; cohort; data management; disease heterogeneity; education research; experience; forest; health disparity; health equity; imaging biomarker; innovation; investigator training; medical schools; neuroimaging; neuropathology; nonhuman primate; normal aging; novel; novel strategies; outreach; prevent; preventive intervention; programs; recruit; repository; resilience; symptom treatment; tau Proteins; translational pipeline; vascular factor; vascular risk factor

Overall – Project Summary The Alzheimer’s Disease Research Center (ADRC) was founded at Wake Forest School of Medicine (WFSM) in 2016 to provide a comprehensive infrastructure for research on the pathophysiology, prevention, and treatment of AD and related disorders (ADRD). The theme of our ADRC is to better understand early transitions from normal aging to MCI and dementia, and to elucidate the role that metabolic and vascular factors play in these transitions, through coordinated research activities spanning the translational spectrum. No current therapies effectively prevent or treat the symptoms of AD. This chasm highlights the need to identify antecedent biomarkers and risk factors that predict later-life vulnerability or resilience, in order to develop strategies for prevention and early intervention. Metabolic and vascular disorders are powerful modifiable factors that may contribute to the transitions from normal aging to MCI and ADRD. Such disorders are epidemic in the Southeastern region surrounding the WF ADRC; more than 70% of adults over the age of 50 have prediabetes, diabetes, or hypertension. These disorders increase the risk of cognitive impairment and dementia through complex interactions that are poorly understood. The WF ADRC seeks to provide resources to better understand these interactions. We also seek to elucidate the multi-dimensional role that health disparities play in influencing risk for AD. We emphasize engagement of African Americans and other underrepresented groups, who are twice as likely to develop dementia, and have high rates of diabetes and vascular disease. To promote innovative research on metabolic/vascular risk and health disparities, our Outreach, Recruitment and Engagement and Clinical Cores have partnered to enroll and follow ~600 participants, carefully characterizing their vascular and glycemic status. Participants receive magnetic resonance imaging and amyloid and tau positron emission tomography overseen by the Imaging Biomarker Core. Valuable samples and data from this cohort are made widely available to the National Alzheimer’s Coordinating Center, the National Centralized Repository for AD and other investigators by the Data Management and Statistical Analysis and Neuropathology Cores, providing invaluable resources to address numerous National Alzheimer’s Project Act milestones. The Neuropathology Core has also characterized novel nonhuman primate models with methods that parallel the ADRC’s human cohort to promote translational research. Finally, the ADRC and its Research Education Component provide training relating to AD, metabolic/ vascular factors and health disparities to a diverse cadre of new researchers, and education for patients and families, health professionals, and the community. The prevalence of metabolic and vascular risk factors, their role in onset, progression, and heterogeneity of ADRDs, and the strengths of the WF ADRC in these research areas, ensure that we will make high-impact contributions to the search for strategies to treat and prevent AD.

总体 – 项目总结 阿尔茨海默病研究中心 (ADRC) 在维克森林医学院 (WFSM) 成立 2016年，为病理生理学、预防和治疗的研究提供全面的基础设施 AD 及相关疾病 (ADRD) 的治疗。我们 ADRC 的主题是尽早更好地了解 从正常衰老到 MCI 和痴呆的转变，并阐明代谢和血管的作用 通过跨转化领域的协调研究活动，各种因素在这些转变中发挥作用。 目前尚无有效预防或治疗 AD 症状的疗法。这一鸿沟凸显了识别的必要性 预测晚年脆弱性或复原力的先行生物标志物和风险因素，以便发展 预防和早期干预策略。代谢和血管疾病是可以有效改变的 可能导致从正常衰老向 MCI 和 ADRD 转变的因素。此类疾病是 WF ADRC周边东南部地区疫情；超过70%的50岁以上成年人 患有糖尿病前期、糖尿病或高血压。这些疾病会增加认知障碍的风险 痴呆症是通过人们知之甚少的复杂相互作用而导致的。 WF ADRC 寻求提供资源 以便更好地理解这些相互作用。我们还试图阐明健康的多维作用 差异对 AD 风险产生影响。我们强调非裔美国人和其他人的参与 代表性不足的群体，他们患痴呆症的可能性是其他群体的两倍，并且糖尿病和糖尿病的发病率很高 血管疾病。为了促进代谢/血管风险和健康差异的创新研究，我们的 外展、招募和参与以及临床核心已合作注册并关注约 600 名 参与者仔细描述他们的血管和血糖状况。参与者收到磁性 由成像生物标志物监测的共振成像以及淀粉样蛋白和 tau 正电子发射断层扫描 核。该队列的宝贵样本和数据已广泛提供给国家阿尔茨海默氏症研究中心 协调中心、国家AD集中存储库和其他研究者的数据 管理和统计分析以及神经病理学核心，提供宝贵的资源来解决 国家阿尔茨海默病项目法案的许多里程碑。神经病理学核心还具有新颖的特征 非人类灵长类动物模型的方法与 ADRC 的人类队列类似，以促进转化 研究。最后，ADRC 及其研究教育部门提供与 AD、代谢/ 向多元化的新研究人员介绍血管因素和健康差异，以及对患者和患者的教育 家庭、卫生专业人员和社区。代谢和血管危险因素的患病率及其影响 ADRD 的发病、进展和异质性中的作用，以及 WF ADRC 在这些研究中的优势 领域，确保我们将为寻找治疗和预防 AD 的策略做出高影响力的贡献。